Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Tomasi, Simone ^a,b   Sarmientos, Paolo ^c   Giorda, Giada ^a,b   Gurewich, Victor ^d   Vercelli, Alessandro ^a,b  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Beth Israel Deaconess Medical Center ^*  (Italy)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BERINERT P; COMPLEMENT COMPONENT C1S INHIBITOR; PLACEBO; PROUROKINASE; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN; SARUPLASE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; IN VITRO STUDY; MALE; NONHUMAN; RAT; STROKE; THROMBOEMBOLISM; ANIMAL; DOG; GUINEA PIG; HUMAN; MUTATION; RABBIT; SPRAGUE DAWLEY RAT;

CANIS FAMILIARIS; RATTUS;

ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; DOGS; GUINEA PIGS; HUMANS; MALE; MUTATION; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STROKE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79960309643     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021999     Document Type: Article

References (52)

1. Murray CJ, Lopez AD, (1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349: 1269-1276.
2. (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581-1587.
3. Yepes M, Roussel BD, Ali C, Vivien D, (2009) Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends in Neurosciences 32: 48-55.
4. Adibhatla RM, Hatcher JF, (2008) Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 7: 243-253.
5. Cronin CA, (2010) Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials. J Emerg Med 38: 99-105.
6. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, et al. (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37: 1399-1406.
7. Sandoval KE, Witt KA, (2008) Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 32: 200-219.
8. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, et al. (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4: 228-231.
9. Wardlaw JM, Sandercock PAG, Berge E, (2003) Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke: Where Do We Go From Here? A Cumulative Meta-Analysis. Stroke 34: 1437-1442.
10. Wang X, (2004) Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke. Stroke 35: 2726-2730.
11. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM, (2004) The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 24: 945-963.
12. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP, (2008) National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 39: 924-928.
13. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, et al. (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282: 2003-2011.
14. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, et al. (1984) Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 73: 1731-1739.
15. (1989) Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet 333: 863-868.
16. Weaver WD, Hartmann JR, Anderson JL, Reddy PS, Sobolski JC, et al. (1994) New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group. J Am Coll Cardiol 24: 1242-1248.
17. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, et al. (1995) Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. J Am Coll Cardiol 26: 374-379.
18. Liu JN, Tang W, Sun ZY, Kung W, Pannell R, et al. (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 35: 14070-14076.
19. Sun Z, Jiang Y, Ma Z, Wu H, Liu BF, et al. (1997) Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. J Biol Chem 272: 23818-23823.
20. Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu J-N, et al. (2006) Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Haemost 4: 1559-1565.
21. Liu J-N, Liu J-X, Liu Bf B-f, Sun Z, Zuo J-L, et al. (2002) Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis. Circulation Research 90: 757-763.
22. Pannell R, Kung W, Gurewich V, (2007) C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost 5: 1047-1054.
23. Gurewich V, Pannell R, (2009) Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis. Thromb Haemost 102: 279-286.
24. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, et al. (1995) Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017-1025.
25. (1997) Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 28: 2109-2118.
26. Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH, (2002) Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 33: 2100-2104.
27. Strbian D, Karjalainen-Lindsberg ML, Kovanen PT, Tatlisumak T, Lindsberg PJ, (2007) Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 116: 411-418.
28. Korninger C, Collen D, (1981) Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46: 561-565.
29. Asahi M, Asahi K, Wang X, Lo EH, (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20: 452-457.
30. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, et al. (2008) Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39: 3372-3377.
31. Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH, (2001) Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 32: 1336-1340.
32. Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, et al. (2006) Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost 95: 166-173.
33. Pannell R, Gurewich V, (1986) Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 67: 1215-1223.
34. Huisman LG, van Griensven JM, Kluft C, (1995) On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 73: 466-471.
35. Pannell R, Black J, Gurewich V, (1988) Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 81: 853-859.
36. Hoylaerts M, Rijken DC, Lijnen HR, Collen D, (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257: 2912-2919.
37. Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW, Verheijen JH, (1983) Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 748: 86-92.
38. Petersen LC, Johannessen M, Foster D, Kumar A, Mulvihill E, (1988) The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage. Biochim Biophys Acta 952: 245-254.
39. Liu JN, Gurewich V, (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 31: 6311-6317.
40. Montoney M, Gardell SJ, Marder VJ, (1995) Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 91: 1540-1544.
41. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, et al. (2003) Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112: 1533-1540.
42. Bennett WR, Yawn DH, Migliore PJ, Young JB, Pratt CM, et al. (1987) Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol 10: 627-632.
43. Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, et al. (2009) The clinical utility index as a practical multiattribute approach to drug development decisions. Clin Pharmacol Ther 86: 105-108.
44. Renolleau S, Aggoun-Zouaoui D, Ben-Ari Y, Charriaut-Marlangue C, (1998) A model of transient unilateral focal ischemia with reperfusion in the P7 neonatal rat: morphological changes indicative of apoptosis. Stroke 29-1454 1460 discussion 1461.
45. Busch E, Krüger K, Hossmann KA, (1997) Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. Brain Res 778: 16-24.
46. Henninger N, Bouley J, Bråtane BT, Bastan B, Shea M, et al. (2009) Laser Doppler flowmetry predicts occlusion but not tPA-mediated reperfusion success after rat embolic stroke. Experimental Neurology 215: 290-297.
47. Longa EZ, Weinstein PR, Carlson S, Cummins R, (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91.
48. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD, (1996) Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke 27: 1616-1622 discussion 1623.
49. Clark WM, Lessov NS, Dixon MP, Eckenstein F, (1997) Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res 19: 641-648.
50. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, et al. (1986) Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17: 1304-1308.
51. Dohare P, Garg P, Jain V, Nath C, Ray M, (2008) Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behavioural Brain Research 193: 289-297.
52. Choudhri TF, Hoh BL, Solomon RA, Connolly ES Jr, Pinsky DJ, (1997) Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke 28: 2296-2302.